

Ref. No: 1351
Date: 14/11/24
Subject: Myeloproliferative neoplasms.

REQUEST

We are researching the treatment of myeloproliferative neoplasms.

Q1. Please provide the total number of patients treated in the last 6 months for:

- Polycythaemia Vera (ICD10 code D45)
- Myelofibrosis (ICD10 code D47.4)
- Myelofibrosis (ICD10 code D47.4) patients aged 65 and older

Q2. How many patients were treated in the past 6 months (for any disease) with:

- Ruxolitinib
- Fedratinib
- Momelotinib

Q3. How many patients were treated with Ruxolitinib in the past 6 months for the following diseases?

- Myelofibrosis (ICD10 code D47.4)
- Polycythaemia Vera (ICD10 code D45)
- Other/Unknown

Q4. How many myelofibrosis (ICD10 code D47.4) patients has your trust diagnosed in the past 3 years?

- Of these patients, how many were treated in the past 6 months with Hydroxycarbamide?
- Of these patients, how many were treated in the past 6 months with Interferon therapy?
- Of these patients, how many have received no active treatment in the past 6 months?

Q5. Does your trust participate in any clinical trials for the treatment of myelofibrosis? If so, can you please provide the name of each trial along with the number of patients taking part.

RESPONSE

MWL response

Q1 Unable to provide an answer as we don't hold information about specific indications

Q2. How many patients were treated in the past 6 months (for any disease) with:

- **Ruxolitinib - 19**
- **Fedratinib - 0**
- **Momelotinib - 6**

Q3 Unable to provide an answer as we don't hold information about specific indications

Q4 Unable to provide an answer as we don't hold information about specific indications

Q5 – No.